Therapies for the treatment of abnormal uterine bleeding.

Jared C. Robins
In: Current women's health reports · 2001 · vol. 1(3) , pp. 196–201 · PMID:12112970 · W2405013772
article OA: closed CC0 ⤵ 4 in-corpus citations
View on OpenAlex View on PubMed
⚙ AI-generated summary by claude@2026-06, 2026-06-09 ⓘ

This review discusses therapies for abnormal uterine bleeding, including NSAIDs, oral contraceptives, tranexamic acid, IUDs, and surgical procedures, noting varying degrees of menstrual blood loss reduction.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Abnormal uterine bleeding (AUB) is one of the most common disorders encountered by the gynecologist. Several drugs have been demonstrated to decrease menstrual bleeding in patients with menorrhagia. Non-steroidal anti-inflammatory drugs will decrease bleeding by 30% to 50%. Oral contraceptives may be useful to stop acute bleeding and will decrease menstrual flow by approximately 50%. Tranexamic acid, a plasminogen inhibitor approved for the treatment of hemophilia, will also decrease flow by approximately 50%. Danazol and GnRH analogues both have been used for the treatment of menorrhagia. However, side effects make them unsuitable for long-term use. There are currently two medicated intrauterine devices (IUDs) available in the United States. These IUDs reduce menstrual blood loss by 65% to 85%. Several minimally invasive surgical procedures, including endometrial resection and ablation, may treat menorrhagia in select patients. More recently, various office-based ablation instruments have been developed. These machines conform to the endometrial cavity and may obviate the need for hysteroscopy.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (4)

References (6)

Cited by (4)

Source provenance

openalex
last seen: 2026-05-11T03:46:51.341007+00:00
License: CC0 · commercial use OK